Shares in Israeli drugmaker VBL Therapeutics dropped up to 55% after it said that it would discontinue developing VB-201 for psoriasis and ulcerative colitis. 18 February 2015
The Chinese treatment market for colorectal cancer (CRC) will expand almost fourfold in value from an estimated $259 million in 2013 to $1.05 billion by 2023, at an impressive compound annual growth rate (CAGR) of 15.1%, a new report shows. 18 February 2015
Israeli generic giant Teva Pharmaceutical Industries has launched a generic equivalent of French pharma major Sanofi’s Lovenox (enoxaparin sodium injection) in seven dosage strengths in the USA. 17 February 2015
US biotech firm Navidea Biopharmaceuticals today announced positive peer-reviewed publication of results from a Phase III clinical trial of Lymphoseek (technetium 99m tilmanocept) injection in patients with certain head and neck cancer (squamous cell carcinoma of the oral cavity. 17 February 2015
In a second research negative this month, Japan’s largest drugmaker Takeda Pharmaceutical has today reported disappointing results with its lung cancer drug candidate motesanib. 17 February 2015
Privately-held US biotech firm Bexion Pharmaceuticals has received Orphan Drug designation for the US Food and Drug Administration for Saposin C, the active ingredient in its proprietary drug BXQ-350 for the potential treatment of glioblastoma multiforme. 17 February 2015
Fresenius Kabi, a unit of the Germany-headquartered Fresenius Group, has sold its German subsidiary CFL GmbH to NewCo Pharma GmbH, a compounding company founded last month by pharmacist Michael Schill. 17 February 2015
UK-based medtech company Angle has raised £7.3 million ($11.2 million) through issuing new shares. It has also announced an offer of new ordinary shares to certain existing shareholders to raise up to an additional £1.5 million. 16 February 2015
The Russian government plans to provide subsidies for the production of pharmaceutical substances for leading national drugmakers this year, according to Alexander Petrov, member of the Committee on Health of the Russian State Duma. 16 February 2015
Japanese pharma company Ono Pharmaceutical and Danish diagnostic provider Dako have signed a new partnership to develop a potential diagnostic test specifically for use with Ono’s Opdivo (nivolumab) in the treatment of non-small cell lung cancer (NSCLC). 16 February 2015
The US Food and Drug Administration on Friday granted approval for Japanese pharma major Eisai’s Lenvima (lenvatinib) to treat patients with progressive, differentiated thyroid cancer (DTC). 14 February 2015
German pharmaceuticals and chemicals major Merck KGaA is to end the co-promotion of Erbitux (cetuximab) in Japan with Bristol-Myers Squibb. 13 February 2015
The England medical costs watchdog the National Institute for Health and Care excellence (NICE) has issued final draft guidance not recommending pomalidomide, marketed by US biotech firm Celgene as Imnovid, for treating multiple myeloma. 13 February 2015
Privately-held US generic drugmaker Breckenridge Pharmaceutical has filed an Abbreviated New Drug Application with the US Food and drug administration, with a Paragraph IV certification for cabazitaxel solution; IV (infusion), a generic version of French pharma major Sanofi’s cancer drug Jevtana. 12 February 2015
Swiss oncology specialist Helsinn has signed an exclusive agreement with Mundipharma to distribute and license anamorelin in Brazil and markets in the Middle East and North Africa. 11 February 2015
A study looking at cancer treatments in France, Italy, Germany, Spain and the UK has been published by health care market research provider Cegedim Strategic Data (CSD). 11 February 2015
US biotech firm Dendreon revealed yesterday that the bid deadline provided by the Court-approved bidding procedures for the sale of substantially all of the company’s assets has expired without receipt of bids additional qualified. 11 February 2015
Japan’s largest drugmaker Takeda Pharmaceutical announced that the randomized, double-blind, placebo-controlled TOURMALINE-MM1 pivotal Phase III trial evaluating the safety and efficacy of ixazomib achieved its primary endpoint of improving progression-free survival at the first pre-specified interim analysis. 10 February 2015
Following a less than flattering financial performance in 2014, UK pharma major GlaxoSmithKline is realigning its operating structure with its corporate objectives and cashing in on its assets in the process, as the company seeks to drive up external investments and deliver stronger shareholder returns in the long term, says an analyst with research and consulting firm GlobalData. 10 February 2015
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024